AAPG
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Ascentage Pharma received U.S. FDA IND clearance for BTK degrader APG-3288Jan 7, 2026
- Ascentage Pharma presents Phase III POLARIS-1 data at ASH 2025 showing over 60% MRD-negativity CR rate in newly diagnosed Ph+ ALLDec 9, 2025
- Ascentage Pharma announces global Phase III study of Olverembatinib cleared by US FDA and EMA for first-line Ph+ ALL treatmentDec 5, 2025